EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Theresa Hunter Gibble iD, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner iD, Mythili Ananth, Karishma Desai iD

Diabetes, Obesity and Metabolism · 2026-11 · 28 (11) · 9966-9979

DOI: 10.1111/dom.71064 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 10.08.2026. Verfasst von Theresa Hunter Gibble und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Tirzepatide, Obesity, Overweight, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large US commercially insured population. Materials and Methods This retrospective, observational study used administrative claims and electronic health records from the Healthcare Integrated Research Database (HIRD). Adults with ≥ 1 prescription claim for tirzepatide (for obesity/overweight, without T2D), between November 2023–June 2024 and continuous medical/pharmacy enrollment for ≥ 12 months pre‐index and ≥ 6 months post‐index were included. Descriptive analyses included baseline demographic and clinical characteristics, treatment patterns and tirzepatide effectiveness (change from baseline in weight, BMI, cardiometabolic risk factors evaluated among persistent individuals) and were stratified by individuals who were GLP‐1 RA naïve and individuals who switched to tirzepatide from a GLP‐1 RA obesity medication.

Results

Of the 22 512 individuals who initiated tirzepatide (mean age: 46 years, 73% female), 55% ( n = 12 292) were adherent (PDC ≥ 80%) and 68% ( n = 15 208) were persistent during the 6‐month follow‐up period. Of the overall population, 91% ( n = 20 554) had ≥ 1 obesity‐related complication at baseline, with dyslipidaemia, hypertension and anxiety being the most frequent complications. Clinically meaningful mean weight reduction (10.5%; n = 808) and numerical reductions in most cardiometabolic risk factors were observed among persistent individuals with available pre‐ and post‐index measurements, including 12.0% body weight reduction in the GLP‐naïve subgroup.

Conclusions

Over half of US adults with obesity or overweight who initiated tirzepatide were adherent (PDC ≥ 80%) and had a favourable persistence profile during a 6‐month follow‐up period. Persistent users achieved clinically meaningful weight reduction and numerical reductions in most cardiometabolic risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirzepatideObesityOverweightGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultUnited StatesDiabetes Mellitus, Type 2Databases, FactualTreatment OutcomeWeight LossAnti-Obesity AgentsHypoglycemic Agents

Stichwörter der Autor:innen

obesityreal‐worldtirzepatideweight reduction

Substanzen

TirzepatideGlucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsHypoglycemic Agents

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Carelon Research, Wilmington, Delaware, USA.

ORCID-Profile: Theresa Hunter Gibble, Michael Grabner, Karishma Desai

Förderung

  • Eli Lilly and Company

Zitieren

APA

Gibble, T. H., Venkataraman, M., Mojdami, D., Vallarino, C., Stockbower, G., Grabner, M., Ananth, M., & Desai, K. (2026). Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis. Diabetes, Obesity and Metabolism, 28(11), 9966-9979. https://doi.org/10.1111/dom.71064

Vancouver

Gibble TH, Venkataraman M, Mojdami D, Vallarino C, Stockbower G, Grabner M, et al. Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis. Diabetes, Obesity and Metabolism. 2026;28(11):9966-9979. doi:10.1111/dom.71064

BibTeX
@article{Gibble2026,
  author = {Gibble, Theresa Hunter and Venkataraman, Malvika and Mojdami, Donna and Vallarino, Carlos and Stockbower, Grace and Grabner, Michael and Ananth, Mythili and Desai, Karishma},
  title = {Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {11},
  pages = {9966--9979},
  doi = {10.1111/dom.71064}
}
Kostenlos starten →